Asialoglycoprotein Receptor 2 Antibody (OTI2A12) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-70212F
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Monoclonal Mouse IgG2B Clone # OTI2A12
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full length recombinant protein of human Asialoglycoprotein Receptor 2 (NP_001172) produced in HEK293T cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for Asialoglycoprotein Receptor 2 Antibody (OTI2A12) [FITC]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: ASGR2
Long Name
Asialoglycoprotein Receptor 2
Alternate Names
ASGPR2, CLEC4H2, HBXBP
Gene Symbol
ASGR2
Additional ASGR2 Products
Product Documents for Asialoglycoprotein Receptor 2 Antibody (OTI2A12) [FITC]
Product Specific Notices for Asialoglycoprotein Receptor 2 Antibody (OTI2A12) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...